The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Invivyd, Inc. is $10.00, about 1,266.1% above its August 12 closing price of $0.73
Outlook and regulatory timeline
Company expects top-line data from DECLARATION and LIBERTY trials in late Q3 2026
Invivyd anticipates cash runway through DECLARATION pivotal data readout and potential VYD2311 launch readiness
PEMGARDA emergency use authorization expected to terminate June 29, 2027; company in dialogue with FDA on next steps
Cost pressures behind the wider loss
PATIENT DEMAND - Co said 21% yr/yr PEMGARDA revenue growth was driven by increased patient demand
CLINICAL TRIAL COSTS - Higher R&D expenses were primarily due to increased contract research costs for DECLARATION and LIBERTY clinical trials
COMMERCIAL AND PERSONNEL EXPENSES - SG&A expenses increased due to higher personnel, communications and commercial-related costs
Quarterly results and revenue drivers
U.S. biopharma firm's Q2 PEMGARDA revenue rose 21% yr/yr on higher patient demand
IVVD•
